首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Advances in atopic dermatitis in 2017
【24h】

Advances in atopic dermatitis in 2017

机译:2017年特应性皮炎进展

获取原文
获取原文并翻译 | 示例
           

摘要

This review encompasses relevant scientific and clinical advances in atopic dermatitis (AD) published in 2017. These include articles from the Journal of Allergy and Clinical Immunology, as well as other prominent publications that have contributed to the emerging field, on the microenvironment of the skin and molecular patterns guiding biologic treatment strategies. The most commonly questioned and explored themes of the year included the effect of the microbiome on AD development, as well as cell signaling and symptom severity. Topics also included the description of patient-specific molecular endotypes within the larger population with AD. All of these factors will create potential opportunities to guide personalized therapy with the broadening array of topical and systemic interventions currently available, as well as providing new insights to guide the development of novel molecularly targeted therapeutics. With recent US Food and Drug Administration approval of the first wave of new targeted therapies for AD, additional information exploring the safety profiles and long-term effects of these medications was also at the forefront in 2017.
机译:本综述包括2017年出版的特应性皮炎(AD)的相关科学和临床进展。这些包括来自过敏和临床免疫学杂志的文章,以及对新兴领域的其他突出出版物,对皮肤的微环境有贡献和分子模式引导生物治疗策略。今年最常见的和探索主题包括微生物组对广告开发的影响,以及细胞信号传导和症状严重程度。主题还包括较大人群中患者特异性分子内型的描述。所有这些因素都将创造潜在的机会,以指导个性化疗法与目前可用的局部和系统干预措施的扩大阵列,并提供新的见解,以指导新的分子靶向治疗的发展。凭借最近的美国食品和药物管理局批准广告的第一波新目标疗法,探索安全概况和这些药物的长期影响的其他信息也在2017年的最前沿。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号